A pilot study of pembrolizumab in smoldering myeloma: report of the clinical, immune, and genomic analysis.
暂无分享,去创建一个
V. Baladandayuthapani | Shaojun Zhang | Guangchun Han | Linghua Wang | Jianhua Zhang | Xingzhi Song | R. Orlowski | B. Amini | R. Mathur | X. Mao | Karina Eterovic | S. Neelapu | Z. Berková | D. Weber | E. Manasanch | A. Futreal | Hans C. Lee | Y. Qing | Zheng Zhang | Lei Feng | M. Morgan | Xingzhi Song | K. Eterovic
[1] N. Puig,et al. Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with Rd , 2018, Blood.
[2] J. Lunceford,et al. IFN-g – related mRNA profile predicts clinical response to PD-1 blockade , 2019 .
[3] Xiaofeng Jiang,et al. X-inactive-specific transcript: A long noncoding RNA with complex roles in human cancers. , 2018, Gene.
[4] Michael L. Wang,et al. Assessment of Safety and Immunogenicity of PVX-410 Vaccine With or Without Lenalidomide in Patients With Smoldering Multiple Myeloma: A Nonrandomized Clinical Trial , 2018, JAMA oncology.
[5] H. Goldschmidt,et al. Updated Results from the Phase 2 Centaurus Study of Daratumumab (DARA) Monotherapy in Patients with Intermediate-Risk or High-Risk Smoldering Multiple Myeloma (SMM) , 2018, Blood.
[6] R. Hájek,et al. Update on PD-1/PD-L1 Inhibitors in Multiple Myeloma , 2018, Front. Immunol..
[7] R. Pazdur,et al. Immunotherapy Combinations in Multiple Myeloma - Known Unknowns. , 2018, The New England journal of medicine.
[8] P. Campbell,et al. Genomic patterns of progression in smoldering multiple myeloma , 2018, Nature Communications.
[9] Eytan Ruppin,et al. Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma , 2018, Nature Medicine.
[10] Michael D. Robbins,et al. Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study , 2018, British journal of haematology.
[11] Christine M. Calton,et al. Oncolytic reovirus sensitizes multiple myeloma cells to anti-PD-L1 therapy , 2017, Leukemia.
[12] W. Wilson,et al. Baseline mutational patterns and sustained MRD negativity in patients with high-risk smoldering myeloma. , 2017, Blood advances.
[13] Y. Asmann,et al. High somatic mutation and neoantigen burden are correlated with decreased progression-free survival in multiple myeloma , 2017, Blood Cancer Journal.
[14] J. Lunceford,et al. IFN-&ggr;–related mRNA profile predicts clinical response to PD-1 blockade , 2017, The Journal of clinical investigation.
[15] W. Dempke,et al. Second- and third-generation drugs for immuno-oncology treatment-The more the better? , 2017, European journal of cancer.
[16] P. Laurent-Puig,et al. Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression , 2016, Genome Biology.
[17] M. Millenson,et al. Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] H. Goldschmidt,et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. , 2016, The Lancet. Oncology.
[19] H. Goldschmidt,et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. , 2016, Blood.
[20] S. Parmar,et al. Use of Gene Expression Profiling May Predict Clinical Outcomes in Newly Diagnosed Multiple Myeloma Patients in a Standard of Care Setting , 2015 .
[21] J. Crowley,et al. Prospective analysis of antigen-specific immunity, stem-cell antigens, and immune checkpoints in monoclonal gammopathy. , 2015, Blood.
[22] M. Stratton,et al. Clock-like mutational processes in human somatic cells , 2015, Nature Genetics.
[23] J. Miguel,et al. PD-L1/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma , 2015, Leukemia.
[24] Gordon Cook,et al. APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma , 2014, Nature Communications.
[25] A. McKenna,et al. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. , 2014, Cancer cell.
[26] B. Barlogie,et al. Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120). , 2014, Blood.
[27] P. L. Bergsagel,et al. Smoldering multiple myeloma requiring treatment: time for a new definition? , 2013, Blood.
[28] David T. W. Jones,et al. Signatures of mutational processes in human cancer , 2013, Nature.
[29] A. Spencer,et al. The t(4;14) translocation and FGFR3 overexpression in multiple myeloma: prognostic implications and current clinical strategies , 2012, Blood Cancer Journal.
[30] M. Gjerstorff,et al. An overview of the GAGE cancer/testis antigen family with the inclusion of newly identified members. , 2008, Tissue antigens.
[31] B. Quesnel,et al. Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. , 2007, Blood.